Do you have a daughter between the ages of 9 and 11 years of age? Researchers at the University of Arizona are conducting a HPV vaccine study that may interest you! HPV is short for human papillomavirus, a common virus. HPV vaccines are usually given as a series of three injections over 6 months to protect against HPV-related cancers and diseases. This new HPV vaccine study is recruiting 9-11 year-old girls to determine if one injection of the HPV vaccine will produce long-term immune response.
The Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE) study is designed as a multi-center international observational, cross sectional study of new cases of PARDS involving 5 continuous days of screening and patient enrollment, occurring every 2 months for a year (6 total study weeks). Included patients will have a new diagnosis of PARDS during the study week or be at risk for PARDS. Data collection will concentrate on the first 3 days of PARDS diagnosis, and follow outcomes such as mortality and length of ventilation.
Optimal delivery of nutritional support during critical illness is central to appropriate intensive care unit management, and yet fundamental gaps in knowledge exist regarding timing, route, dose, and type of nutritional support for critically ill infants and children. Understanding how to optimize nutritional support during pediatric critical illness is important because even brief periods of malnutrition in infancy result in permanent negative effects on long-term neurocognitive development.
Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to be able to develop into the various cell types that make up the human body. Skin biopsies taken from pediatric patients with rare neurodegenerative disorders and age matched controls will be used to generate patient specific iPSC cell lines. These cell lines will then be developed into various neuronal cell populations in order to study the genetic cause of these rare and incurable diseases.
1.1.1 To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone.
1.2 Secondary Aims
1.2.1 To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy